Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AR100DP1 in Healthy Subjects and Mild to Moderate Atopic Dermatitis
NCT04220411Phase 2Terminated
- Sponsor
- ARJIL Pharmaceuticals
- Start
- Dec 2020
- Primary completion
- Dec 2021
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ovatodiolide in atopic dermatitis (AD), sponsored by ARJIL Pharmaceuticals. Started Dec 2020; status: terminated.
02
Drugs
ovatodiolide
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04220411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04220411.